{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:56Z","timestamp":1772166416293,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"crossref","award":["2018YFC1705700"],"award-info":[{"award-number":["2018YFC1705700"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Chronic hepatitis B (CHB) is a global public health problem. Antiviral therapy is the primary treatment. Studies have shown that a combined therapy of traditional Chinese medicine (TCM) and conventional antiviral drugs has better efficacy than conventional antiviral for treatment of CHB.\n                      <jats:italic>YinQiSanHuang<\/jats:italic>\n                      -antiviral decoction (YQSH) is a TCM compound preparation that has shown an effect on anti-hepatitis B virus and on slowing progression of hepatitis B-related liver diseases. To evaluate the efficacy and safety of YQSH combined with entecavir and its preventive effect on hepatitis B cirrhosis, we designed this randomized, double-blind and placebo-controlled trial. The objective is that the combination of YinQiSanHuang-antiviral decoction with entecavir will reduce the annual incidence of liver fibrosis\/cirrhosis to 1%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a multicenter, randomized, placebo-controlled, double-blinded trial involving five hospitals. A total of 802 patients are randomly allocated to two groups: the YQSH group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009401) or the placebo group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009401). The YQSH group receives YQSH with entecavir; the placebo group receives granules of placebo with entecavir. Patients receive treatment for 52\u2009weeks and then are followed up for 52\u2009\u00b1\u20092\u2009weeks. The primary outcome measure is the annual incidence of cirrhosis. The secondary outcome measures are hepatitis B virus DNA negative rate, hepatitis B surface antigen negative rate, hepatitis B e antigen seroconversion rate, liver function (alanine aminotransferase, aspartate aminotransferase , gamma-glutamyl transferase , alkaline phosphatase , serum albumin, and total bilirubin), spleen thickness, evaluation scores of patients\u2019 clinical symptoms, and safety assessment. Outcomes will be assessed at baseline and after treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Combination therapy could become a trend for treatment of CHB, and this trial expects to provide credible clinical evidence for the future combination of TCM and conventional antiviral drugs for the treatment of CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Chinese Clinical Trial Registry:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/searchproj.aspx\">ChiCTR1900021521<\/jats:ext-link>\n                      . Registered on 25 February 2019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-020-04395-y","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T09:02:39Z","timestamp":1591347759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Qing-Juan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4552-919X","authenticated-orcid":false,"given":"Wen-Liang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiu-Chong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gao-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Min","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"4","key":"4395_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/genes10040260","volume":"10","author":"PA Revill","year":"2019","unstructured":"Revill PA, Penicaud C, Brechot C, et al. Meeting the challenge of eliminating chronic hepatitis B infection. Genes (Basel). 2019;10(4):260.","journal-title":"Genes (Basel)"},{"key":"4395_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546\u201355.","journal-title":"Lancet"},{"key":"4395_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","volume":"97","author":"J Liu","year":"2019","unstructured":"Liu J, Liang WN, Jing WZ, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97:230\u20138.","journal-title":"Bull World Health Organ"},{"key":"4395_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cld.2019.04.008","volume":"23","author":"A Vittal","year":"2019","unstructured":"Vittal A, Ghany MG. WHO guidelines for prevention, care and treatment of individuals infected with HBV: a US perspective. Clin Liver Dis. 2019;23:417\u201332.","journal-title":"Clin Liver Dis"},{"key":"4395_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081\u20138.","journal-title":"Lancet"},{"key":"4395_CR6","first-page":"16","volume":"2","author":"M Dandri","year":"2012","unstructured":"Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut. 2012;2:16\u20137.","journal-title":"Gut"},{"key":"4395_CR7","doi-asserted-by":"publisher","unstructured":"Won LS, Hyun KJ, Lim LH, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis[J]. Gut. 2019;0:1\u20138. https:\/\/doi.org\/10.1136\/gutjnl-2019-318947.","DOI":"10.1136\/gutjnl-2019-318947"},{"key":"4395_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1086\/656624","volume":"51","author":"D Bhattacharya","year":"2010","unstructured":"Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis. 2010;51:1201\u20138.","journal-title":"Clin Infect Dis"},{"key":"4395_CR9","first-page":"5","volume":"01","author":"S Shan","year":"2017","unstructured":"Shan S, Jia J. Advances and challenge in prevention and treatment of hepatitis B in China. Zhongguo Bingdubing Zazhi. 2017;01:5\u20138.","journal-title":"Zhongguo Bingdubing Zazhi"},{"issue":"Suppl 1","key":"4395_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/liv.13640","volume":"38","author":"M Subic","year":"2018","unstructured":"Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int. 2018;38(Suppl 1):115\u201321.","journal-title":"Liver Int"},{"key":"4395_CR11","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","volume":"156","author":"F Yuen M","year":"2019","unstructured":"Yuen M F, Gane E J, Kim D J, et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology. 2019;156:1392\u2013403.","journal-title":"Gastroenterology"},{"key":"4395_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.12395","volume":"34","author":"V Calvaruso","year":"2014","unstructured":"Calvaruso V, Crax\u00ec A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int. 2014;34:85\u201390.","journal-title":"Liver Int"},{"key":"4395_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejmech.2018.02.001","volume":"147","author":"DJ Sun","year":"2018","unstructured":"Sun DJ, Zhu LJ, Yao DH, et al. Recent progress in potential anti-hepatitis B virus agents: structural and pharmacological perspectives. Eur J Med Chem. 2018;147:205\u201317.","journal-title":"Eur J Med Chem"},{"key":"4395_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3851\/IMP3169","volume":"23","author":"SH Lee","year":"2018","unstructured":"Lee SH, Cheon GJ, Kim HS, et al. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicenter trial. Antivir Ther. 2018;23:219\u201327.","journal-title":"Antivir Ther"},{"key":"4395_CR15","doi-asserted-by":"publisher","first-page":"e014571","DOI":"10.1136\/bmjopen-2016-014571","volume":"7","author":"TY Tsai","year":"2017","unstructured":"Tsai TY, Livneh H, Hung TH, et al. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7:e014571.","journal-title":"BMJ Open"},{"key":"4395_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jep.2014.08.043","volume":"156","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Geng CA, Ma YB, et al. UFLC\/MS-IT-TOF guided isolation of anti-HBV active chlorogenic acid analogues from Artemisia capillaris as a traditional Chinese herb for the treatment of hepatitis. J Ethnopharmacol. 2014;156:147\u201354.","journal-title":"J Ethnopharmacol"},{"key":"4395_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.etp.2012.12.002","volume":"65","author":"JM Han","year":"2013","unstructured":"Han JM, Kim HG, Choi MK, et al. Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats. Exp Toxicol Pathol. 2013;65:837\u201344.","journal-title":"Exp Toxicol Pathol"},{"key":"4395_CR18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/jphp.13129","volume":"71","author":"TT Zhao","year":"2019","unstructured":"Zhao TT, Tang HL, Xie L, et al. Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. J Pharm Pharmacol. 2019;71:1353\u201369.","journal-title":"J Pharm Pharmacol"},{"key":"4395_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jep.2014.05.053","volume":"155","author":"HS Park","year":"2014","unstructured":"Park HS, Park KI, Hong GE, et al. Korean Scutellaria baicalensis Georgi methanol extracts inhibits metastasis via the Forkhead Box M1 activity in hepatocellular carcinoma cells. J Ethnopharmacol. 2014;155:847\u201351.","journal-title":"J Ethnopharmacol"},{"key":"4395_CR20","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1111\/j.1440-1746.2008.05390.x","volume":"23","author":"YL Hsu","year":"2008","unstructured":"Hsu YL, Kuo PL, Tzeng TF, et al. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo. J Gastroenterol Hepatol. 2008;23:e290\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"4395_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1142\/S0192415X97000093","volume":"25","author":"Y Ohta","year":"1997","unstructured":"Ohta Y, Sasaki E, Nishida K, et al. Preventive effect of oren-gedoku-to (huanglian-jie-du-tang) extract on progression of carbon tetrachloride-induced acute liver injury in rats. Am J Chin Med. 1997;25:57\u201368.","journal-title":"Am J Chin Med"},{"key":"4395_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"4395_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u201383.","journal-title":"Hepatology"},{"key":"4395_CR24","doi-asserted-by":"publisher","first-page":"112132","DOI":"10.1016\/j.jep.2019.112132","volume":"244","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Ren X, Chen M, et al. Effects of traditional Chinese medicine formula Le-Cao-Shi on hepatitis B: in vivo and in vitro studies. J Ethnopharmacol. 2019;244:112132.","journal-title":"J Ethnopharmacol"},{"key":"4395_CR25","doi-asserted-by":"publisher","first-page":"44788","DOI":"10.1038\/srep44788","volume":"7","author":"JB Wang","year":"2017","unstructured":"Wang JB, Liu R, Liu BX, et al. Systems pharmacology-based strategy to screen new adjuvant for hepatitis B vaccine from Traditional Chinese Medicine Ophiocordyceps sinensis. Sci Rep. 2017;7:44788.","journal-title":"Sci Rep"},{"key":"4395_CR26","unstructured":"Wang DP. Clinical study of Yinzhi Sanhuang Jiedu Decoction combined with entecavir in the treatment of chronic hepatitis B. Beijing: Beijing University of Chinese Medicine; 2018. p. 63\u20134."},{"key":"4395_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263\u201383.","journal-title":"Hepatol Int"},{"key":"4395_CR28","first-page":"55","volume-title":"National standards for TCM clinical diagnosis and treatment in the People\u2019s Republic of China: symptoms section","author":"State Bureau of Technical Supervision","year":"1997","unstructured":"State Bureau of Technical Supervision. National standards for TCM clinical diagnosis and treatment in the People\u2019s Republic of China: symptoms section, vol. 4. Beijing: China Standard Press; 1997. p. 55."},{"key":"4395_CR29","first-page":"277","volume":"19","author":"Chinese Society of Integrated Traditional and Western Medicine, Digestive System Diseases Committee","year":"2011","unstructured":"Chinese Society of Integrated Traditional and Western Medicine, Digestive System Diseases Committee. Consensus on diagnosis and treatment of cirrhosis with integrated traditional Chinese and Western medicine. Chin J Integr Traditional Western Med Digestion. 2011;19:277\u20139.","journal-title":"Chin J Integr Traditional Western Med Digestion"},{"issue":"2","key":"4395_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","volume":"48","author":"G Fattovich","year":"2008","unstructured":"Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335\u201352.","journal-title":"J Hepatol"},{"key":"4395_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1515\/hsz-2017-0118","volume":"398","author":"T Tu","year":"2017","unstructured":"Tu T, Sandra B, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem. 2017;398:817\u201337.","journal-title":"Biol Chem"},{"key":"4395_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531\u201361.","journal-title":"Hepatol Int"},{"key":"4395_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1055\/s-0037-1606212","volume":"37","author":"B Testoni","year":"2017","unstructured":"Testoni B, Levrero M, Zoulim F. Challenges to a cure for HBV infection. Semin Liver Dis. 2017;37:231\u201342.","journal-title":"Semin Liver Dis"},{"key":"4395_CR34","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","volume":"67","author":"AS Lok","year":"2017","unstructured":"Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: from discovery to regulatory approval. J Hepatol. 2017;67:847\u201361.","journal-title":"J Hepatol"},{"key":"4395_CR35","first-page":"482","volume":"15","author":"M He","year":"2016","unstructured":"He M, Wu Y, Wang MM, et al. Meta-analysis of the clinical value of oxymatrine on sustained virological response in chronic hepatitis B. Ann Hepatol. 2016;15:482\u201391.","journal-title":"Ann Hepatol"},{"key":"4395_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jhep.2014.03.009","volume":"61","author":"L Zhang","year":"2014","unstructured":"Zhang L, Schuppan D. Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype. J Hepatol. 2014;61:166\u20138.","journal-title":"J Hepatol"},{"key":"4395_CR37","doi-asserted-by":"publisher","first-page":"9395","DOI":"10.1038\/srep09395","volume":"5","author":"H Kang","year":"2015","unstructured":"Kang H, Zhao Y, Li C, et al. Integrating clinical indexes into four-diagnostic information contributes to the Traditional Chinese Medicine (TCM) syndrome diagnosis of chronic hepatitis B. Sci Rep. 2015;5:9395.","journal-title":"Sci Rep"},{"key":"4395_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/1534735416660617","volume":"16","author":"JX Chen","year":"2017","unstructured":"Chen JX, Xu QX, Wang JH, et al. A case of recurrent hepatocellular carcinoma acquiring complete remission of target lesion with treatment with Traditional Chinese Medicine. Integr Cancer Ther. 2017;16:597\u2013604.","journal-title":"Integr Cancer Ther"},{"key":"4395_CR39","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/hr.2013.18","volume":"36","author":"X Xiong","year":"2013","unstructured":"Xiong X, Yang X, Liu Y, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertension Res. 2013;36:570\u20139.","journal-title":"Hypertension Res"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-020-04395-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T19:28:13Z","timestamp":1622834893000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04395-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4395"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04395-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.20189\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.20189\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol has been approved by the Medical Ethics Committee of Hangzhou Xixi Hospital, China (for central ethical approval), and the other centers in the trial will not begin recruiting until local ethical approval has been obtained. All study participants will sign two informed consent forms, one kept by the patients and the other kept by the researcher. The results of this study will be published in a peer-reviewed journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"According to the terms of the informed consent, unless the subject\u2019s consent is obtained, all the subject\u2019s personal information is confidential and will not be disclosed to the public. When it is necessary, the drug supervision and administration department, ethics committee, or project funding department may consult the subject\u2019s data. Without permission, they will not use the subject\u2019s information for other purposes or disclose it to other groups.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"482"}}